Recent Updates
Recently added Catalysts
BAX Positive Sentiment

Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors

Thursday, July 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Baxter International Inc. will conduct a conference call on July 30, 2026, to discuss its second-quarter financial results. The call is scheduled for 7:30 a.m. Central Time and will be accessible via pre-registration. Investors can also listen to the call through Baxter's website.
Price reaction · baseline $22.46 (2026-07-09 close) · hit after-hours · clean, no other BAX news in the window
day 0 close
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Baxter is actively engaging with investors.
  • The company is providing timely updates on financial performance.
  • The conference call format allows for broader participation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
2.1%
average across 13 past catalysts
Lead asset
Glycerophosphate
Phase 1 · Parenteral Nutrition

Full Press Release Details

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/167756971 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter’s website at www.bax

Frequently Asked Questions

When is Baxter's Q2 2026 financial results call?

The call is scheduled for July 30, 2026, at 7:30 a.m. Central Time.

How can I participate in the conference call?

You can pre-register for the call using the provided link to receive call information.

Will the conference call be available online?

Yes, the call will be webcast and accessible through Baxter's website.

ShareAdd on Google
Tags: BAX Baxter financial results conference call investors Q2 2026
Last updated: Jul 9, 2026

Biotech snapshot

Cash runway
$2150M liquidity · $0M/mo burn
Low dilution risk
Lead asset
GlycerophosphatePhase 1
Parenteral Nutrition →

Catalyst track record

+71%
best trade around BAX's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for BAX.

See every catalyst's timing & PoA →